Analysis of information received during treatment and adherence to tamoxifen in breast cancer patients
This study examines whether women with breast cancer, who are adherent and non-adherent to tamoxifen, differ in their perceptions of information received during treatment. This cross-sectional study included women receiving tamoxifen as adjuvant treatment for breast cancer recruited from a teaching...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Termedia Publishing House
2017-12-01
|
| Series: | Contemporary Oncology |
| Subjects: | |
| Online Access: | https://www.termedia.pl/Analysis-of-information-received-during-treatment-and-adherence-to-tamoxifen-in-breast-cancer-patients,3,31357,1,1.html |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850178592254722048 |
|---|---|
| author | Aline Cruz Aline Rodrigues Amanda Ferracini Rebeca Stahlschmidt Nice Silva Priscila Mazzola |
| author_facet | Aline Cruz Aline Rodrigues Amanda Ferracini Rebeca Stahlschmidt Nice Silva Priscila Mazzola |
| author_sort | Aline Cruz |
| collection | DOAJ |
| description | This study examines whether women with breast cancer, who are adherent and non-adherent to tamoxifen, differ in their perceptions of information received during treatment. This cross-sectional study included women receiving tamoxifen as adjuvant treatment for breast cancer recruited from a teaching hospital specialised in women’s health in the state of São Paulo (Brazil). Women were interviewed and their records were reviewed for socio demographic data and clinical characteristics. We assessed tamoxifen adherence using the Morisky-Green Test, and the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire – Information module (EORTC QLQ-INFO25) was used to evaluate the information received by the women. The sample contained 31 women (mean age = 55.4; SD = 11.6 years). According to the Morisky-Green Test, 74.2% of the women had suboptimal tamoxifen adherence. The global score for women’s perceptions of information they received about the treatment and disease was 57.0 ±19.1 on a scale of 0 to 100, and no significant differences in scores were observed between adherents and non-adherents. A high prevalence of suboptimal tamoxifen adherence was observed. We found no significant differences between women with breast cancer who were adherent and non-adherent to tamoxifen. |
| format | Article |
| id | doaj-art-b48be40c42a04e749a93d8a6366fb8ab |
| institution | OA Journals |
| issn | 1428-2526 1897-4309 |
| language | English |
| publishDate | 2017-12-01 |
| publisher | Termedia Publishing House |
| record_format | Article |
| series | Contemporary Oncology |
| spelling | doaj-art-b48be40c42a04e749a93d8a6366fb8ab2025-08-20T02:18:42ZengTermedia Publishing HouseContemporary Oncology1428-25261897-43092017-12-0121429529810.5114/wo.2017.7239731357Analysis of information received during treatment and adherence to tamoxifen in breast cancer patientsAline CruzAline RodriguesAmanda FerraciniRebeca StahlschmidtNice SilvaPriscila MazzolaThis study examines whether women with breast cancer, who are adherent and non-adherent to tamoxifen, differ in their perceptions of information received during treatment. This cross-sectional study included women receiving tamoxifen as adjuvant treatment for breast cancer recruited from a teaching hospital specialised in women’s health in the state of São Paulo (Brazil). Women were interviewed and their records were reviewed for socio demographic data and clinical characteristics. We assessed tamoxifen adherence using the Morisky-Green Test, and the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire – Information module (EORTC QLQ-INFO25) was used to evaluate the information received by the women. The sample contained 31 women (mean age = 55.4; SD = 11.6 years). According to the Morisky-Green Test, 74.2% of the women had suboptimal tamoxifen adherence. The global score for women’s perceptions of information they received about the treatment and disease was 57.0 ±19.1 on a scale of 0 to 100, and no significant differences in scores were observed between adherents and non-adherents. A high prevalence of suboptimal tamoxifen adherence was observed. We found no significant differences between women with breast cancer who were adherent and non-adherent to tamoxifen.https://www.termedia.pl/Analysis-of-information-received-during-treatment-and-adherence-to-tamoxifen-in-breast-cancer-patients,3,31357,1,1.htmlmedication adherence quality of life breast cancer tamoxifen |
| spellingShingle | Aline Cruz Aline Rodrigues Amanda Ferracini Rebeca Stahlschmidt Nice Silva Priscila Mazzola Analysis of information received during treatment and adherence to tamoxifen in breast cancer patients Contemporary Oncology medication adherence quality of life breast cancer tamoxifen |
| title | Analysis of information received during treatment and adherence to tamoxifen in breast cancer patients |
| title_full | Analysis of information received during treatment and adherence to tamoxifen in breast cancer patients |
| title_fullStr | Analysis of information received during treatment and adherence to tamoxifen in breast cancer patients |
| title_full_unstemmed | Analysis of information received during treatment and adherence to tamoxifen in breast cancer patients |
| title_short | Analysis of information received during treatment and adherence to tamoxifen in breast cancer patients |
| title_sort | analysis of information received during treatment and adherence to tamoxifen in breast cancer patients |
| topic | medication adherence quality of life breast cancer tamoxifen |
| url | https://www.termedia.pl/Analysis-of-information-received-during-treatment-and-adherence-to-tamoxifen-in-breast-cancer-patients,3,31357,1,1.html |
| work_keys_str_mv | AT alinecruz analysisofinformationreceivedduringtreatmentandadherencetotamoxifeninbreastcancerpatients AT alinerodrigues analysisofinformationreceivedduringtreatmentandadherencetotamoxifeninbreastcancerpatients AT amandaferracini analysisofinformationreceivedduringtreatmentandadherencetotamoxifeninbreastcancerpatients AT rebecastahlschmidt analysisofinformationreceivedduringtreatmentandadherencetotamoxifeninbreastcancerpatients AT nicesilva analysisofinformationreceivedduringtreatmentandadherencetotamoxifeninbreastcancerpatients AT priscilamazzola analysisofinformationreceivedduringtreatmentandadherencetotamoxifeninbreastcancerpatients |